retatrutide safety retatrutide clinical trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II New GLP-3 drug significantly slashes

FAQ 4: Are certain GLP-1 medications more likely to cause hair loss than others

Others pointed to obesity

[1] It is important to note that weight loss was smaller in participants with type 2 diabetes, consistent with findings seen with other agents in this class

PlexusDx patients achieve comparable weight loss results at a fraction of the cost

So I tried a few things I had in my toolbox to get a bit more space to better see the play

Their salutary and what appears to be marked impact beyond losing weight is getting validated in ways not fully anticipated, affecting cardiovascular outcomes, non-alcoholic fatty liver disease, and perhaps substance and behavioral addiction